CCM
AVIR icon

Cloud Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

Cloud Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-59
Closed – – 224
2025
Q3 		$0 Buy
+59
New +$201 ﹤0.01% 1026

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cloud Capital Management's AVIR Position: Q4 2025 in Review

Cloud Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2025, closing a stake of 59 shares.

Cloud Capital Management first reported a position in AVIR in Q3 2025 and held it in 1 quarter. The position peaked at $0 in Q3 2025. 111 funds tracked by Wall St. Rank hold AVIR as of Q4 2025.

  • Cloud Capital Management reported no remaining Atea Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Cloud Capital Management sold 59 Atea Pharmaceuticals shares in Q4 2025.
  • Cloud Capital Management first reported a position in Atea Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Cloud Capital Management's Atea Pharmaceuticals position peaked at $0 in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2025.

Based on Cloud Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.